BRPI0612632A2 - anticorpos do receptor anti-ccr7 para o tratamento de cÂncer - Google Patents

anticorpos do receptor anti-ccr7 para o tratamento de cÂncer Download PDF

Info

Publication number
BRPI0612632A2
BRPI0612632A2 BRPI0612632-4A BRPI0612632A BRPI0612632A2 BR PI0612632 A2 BRPI0612632 A2 BR PI0612632A2 BR PI0612632 A BRPI0612632 A BR PI0612632A BR PI0612632 A2 BRPI0612632 A2 BR PI0612632A2
Authority
BR
Brazil
Prior art keywords
ccr7
cells
antibody
cell
receptor
Prior art date
Application number
BRPI0612632-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Cecilia Munoz Calleja
Manuel Jesus Alfonso Perez
Sonia Lopez Giral
Original Assignee
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Madrid Autonoma filed Critical Univ Madrid Autonoma
Publication of BRPI0612632A2 publication Critical patent/BRPI0612632A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0612632-4A 2005-07-06 2006-07-05 anticorpos do receptor anti-ccr7 para o tratamento de cÂncer BRPI0612632A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/007371 2005-07-06
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0612632A2 true BRPI0612632A2 (pt) 2012-01-03

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612632-4A BRPI0612632A2 (pt) 2005-07-06 2006-07-05 anticorpos do receptor anti-ccr7 para o tratamento de cÂncer

Country Status (16)

Country Link
US (1) US8066996B2 (cg-RX-API-DMAC10.html)
EP (1) EP1904102B1 (cg-RX-API-DMAC10.html)
JP (1) JP5249025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080030655A (cg-RX-API-DMAC10.html)
CN (1) CN101257923A (cg-RX-API-DMAC10.html)
AT (1) ATE453407T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006265281C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612632A2 (cg-RX-API-DMAC10.html)
CA (1) CA2614080C (cg-RX-API-DMAC10.html)
DE (1) DE602006011466D1 (cg-RX-API-DMAC10.html)
DK (1) DK1904102T3 (cg-RX-API-DMAC10.html)
ES (1) ES2338919T3 (cg-RX-API-DMAC10.html)
IL (1) IL188594A (cg-RX-API-DMAC10.html)
PT (1) PT1904102E (cg-RX-API-DMAC10.html)
RU (1) RU2404808C2 (cg-RX-API-DMAC10.html)
WO (2) WO2007003216A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102663440B1 (ko) * 2015-08-10 2024-05-07 펩맵 비.브이. 인간화된 항-ccr7 리셉터 항체
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP2022514867A (ja) * 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten

Also Published As

Publication number Publication date
IL188594A (en) 2012-02-29
CN101257923A (zh) 2008-09-03
AU2006265281B2 (en) 2012-03-01
EP1904102B1 (en) 2009-12-30
DK1904102T3 (da) 2010-04-19
ATE453407T1 (de) 2010-01-15
CA2614080A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
WO2007003216A1 (en) 2007-01-11
US20090123483A1 (en) 2009-05-14
PT1904102E (pt) 2010-03-29
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
EP1904102A1 (en) 2008-04-02
AU2006265281C1 (en) 2012-11-15
KR20080030655A (ko) 2008-04-04
RU2008104420A (ru) 2009-08-20
JP5249025B2 (ja) 2013-07-31
DE602006011466D1 (de) 2010-02-11
ES2338919T3 (es) 2010-05-13
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR101979208B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
JP2019110906A (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
ES2878749T3 (es) Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
US8187594B2 (en) Transferrin receptor antibodies
JP7090545B2 (ja) Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
KR20160090893A (ko) Ccr9에 대한 항체 및 그의 적용방법
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
BR112020022265A2 (pt) método para tratar câncer em um indivíduo, e, estojo.
EP3094654B1 (en) Targeting clptm1l for treatment and prevention of cancer
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
TWI743469B (zh) 抗ｇｉｔｒ抗體及其用途
US12622976B2 (en) Targeting CLPTM1L for treatment and prevention of cancer
WO2025106278A1 (en) Treatment of cancer using b7-h4-targeted antibody-drug conjugates
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
BR112020001320A2 (pt) combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
KR20240099363A (ko) 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
HK40124330B (en) Anti-cd39 antibodies and use thereof
CN119677779A (zh) 抗核仁磷蛋白1抗体和抗体缀合物组合治疗
BRPI0901452A2 (pt) métodos para o tratamento de leucemia mielóide aguda

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL